Malaysia Insulin Infusion Pump Market Size and Share
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| Market Size (2025) | USD 0.83 Million |
| Market Size (2030) | USD 0.94 Million |
| CAGR (2025 - 2030) | 2.60% |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Malaysia Insulin Infusion Pump Market Analysis by Mordor Intelligence
The Malaysia Insulin Infusion Pump Market size is estimated at USD 0.83 million in 2025, and is expected to reach USD 0.94 million by 2030, at a CAGR of 2.6% during the forecast period (2025-2030).
According to the Agency for Clinical Research (ICR), a research agency affiliated with the National Institutes of Health (NIH), seven out of ten patients who died from COVID-19 in Malaysia had diabetes. The NHMS also discovered that around 8.1% of Malaysia's adult population, or 1.7 million people, have all three risk factors for diabetes, hypertension, and high cholesterol, the three major noncommunicable illnesses. Diabetes, according to STAT, is characterized by a chronic inflammatory condition that may result in a greater response to COVID-19 or an immunological overreaction that may cause organ damage. Diabetes can also compromise the immune system, and people with type-2 diabetes have more ACE2 receptors in numerous organs, making them more vulnerable to COVID-19 invasion.
Regarding diabetes gadgets, the monitoring category has a substantial market share. Over 100 million individuals worldwide need insulin, including all Type-1 diabetics and 10% to 25% of Type-2 diabetics, who are all required to regularly monitor their glucose levels. Insulin production is exceedingly complex, with just a few manufacturers on the market. As a result, there is fierce competition among these businesses, which always strive to match patient demands by providing the highest-quality insulin.
According to the National Diabetes Registry (NDR) of the Ministry of Health, 84% of diabetes patients in Malaysia are overweight, with young Malaysians aged 18 to 40 being among them. The government is currently investigating the Sama-Sama project, which aims to empower family members and carers to help individuals living with diabetes to enhance disease control and outcomes.
In reality, underlying comorbidities account for most coronavirus mortality in Malaysia, with diabetes and hypertension topping the list and driving the market throughout the forecast period.
Malaysia Insulin Infusion Pump Market Trends and Insights
Insulin Pump is Expected to Witness Growth Over the Forecast Period
An insulin pump is a device that continuously or, as needed, distributes insulin. The pump is modeled after the human pancreas. The insulin infusion pump can be used instead of a daily injection regimen or an insulin pen. Insulin pump treatment is a popular technique of insulin delivery for people with type 1 diabetes (T1DM). Pumps are a well-known and tried-and-true therapeutic option for T1DM patients of all ages, providing near-physiological insulin administration when the pancreas fails to generate insulin. Remote-controlled insulin pumps allow parents to suspend or bolus insulin from a safe distance while their child is playing or eating.
The government is collaborating with the private sector to develop a program to train healthcare staff and, eventually, carers. Malaysia has the highest diabetes incidence in the Western Pacific and one of the highest in the world, with an annual cost of more than 600 million US dollars. Several variables, including population increase, aging, urbanization, and growing obesity and physical inactivity, contribute to the emerging trend. The growing prevalence of diabetes and its effects in Malaysia motivated this study to comprehensively identify, define, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Insulin therapy is the most effective hypoglycemic drug for diabetes treatment; nonetheless, insulin strength deteriorates when inadequately managed. NCDs, including diabetes, are responsible for more than 70% of all fatalities in Malaysia.
The growing prevalence of diabetes and its effects in Malaysia prompted this study to comprehensively identify, characterize, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Although the use of insulin pumps has expanded dramatically in the West, particularly among type 1 diabetics, it is still quite restricted in Malaysia. The basal insulin infusion, which replaces intermediate- or long-acting subcutaneous insulin injections, delivers insulin continuously throughout the day at predetermined rates adjusted based on the individual's needs.
Owing to the above factors, the market will likely continue to grow.
Rising diabetes prevalence in the country is anticipated to boost the market studied
Diabetes and prediabetes are rising in Malaysia; thus, the government is implementing diabetes prevention and control campaigns nationwide. The Malaysian government should take a comprehensive approach and plan to enhance diabetes awareness, control, prevention, and treatment to minimize the incidence of diabetes in the country. Overweight and obesity contribute significantly to Malaysia's younger diabetic population.
According to the National Health and Nutrition Survey, one in every two Malaysian people is overweight or obese. Diabetes patients have excessive levels of glucose or sugar in their blood. It is a condition caused by the body's inability to produce enough insulin to manage blood sugar levels. It can also be caused by the body's inefficient insulin utilization, known as insulin resistance. Obesity, bad eating habits, sedentary lifestyles, and heredity influence this process.
The government is working with the commercial sector on a program to train healthcare personnel and, eventually, carers. The government is currently investigating the Sama-Sama project, which aims to empower family members and carers to help individuals living with diabetes to enhance disease control and outcomes. It is also working with the private sector on a training program.
As a result, Malaysia's Insulin Pump Devices market is predicted to expand gradually in the coming years.
Competitive Landscape
Due to the existence of only a few big businesses operating internationally and locally, the insulin infusion pump industry is concentrated. The competitive landscape includes examining a few well-known worldwide and local organizations, such as Medtronic PLC, Insulet Corporation, Ypsomed, Ascensia Diabetes Care, and Tandem Diabetes Care.
Malaysia Insulin Infusion Pump Industry Leaders
-
Medtronics
-
Ascensia Diabetes Care
-
Insulet Corporation
-
Tandem Diabetes Care
-
Ypsomed
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- April 2023: Medtronic plc announced U.S. Food and Drug Administration (FDA) approval of its MiniMed 780G system with the Guardian 4 sensor requiring no fingersticks while in SmartGuard technology.
- May 2023: Medtronic plc announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch device - a tubeless, wearable, and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more individuals with diabetes.
Malaysia Insulin Infusion Pump Market Report Scope
An insulin pump delivers insulin to control blood sugar and minimize hypoglycemia's effects. The pump comprises a pump reservoir like an insulin cartridge, a battery-operated pump, and a computer chip that allows the user to control the exact amount of insulin being delivered. The pump is attached to a thin plastic tube (an infusion set) with a soft cannula (or needle) at the end through which insulin passes. Malaysia's insulin infusion pumps market is segmented by components (pump device, infusion set, and reservoir). The report offers the value (USD) and Volume (units) for the above segments.
| Insulin Pump Device |
| Infusion Set |
| Reservoir |
| Insulin Infusion Pump | Insulin Pump Device |
| Infusion Set | |
| Reservoir |
Key Questions Answered in the Report
How big is the Malaysia Insulin Infusion Pump Market?
The Malaysia Insulin Infusion Pump Market size is expected to reach USD 0.83 million in 2025 and grow at a CAGR of 2.60% to reach USD 0.94 million by 2030.
What is the current Malaysia Insulin Infusion Pump Market size?
In 2025, the Malaysia Insulin Infusion Pump Market size is expected to reach USD 0.83 million.
Who are the key players in Malaysia Insulin Infusion Pump Market?
Medtronics, Ascensia Diabetes Care, Insulet Corporation, Tandem Diabetes Care and Ypsomed are the major companies operating in the Malaysia Insulin Infusion Pump Market.
What years does this Malaysia Insulin Infusion Pump Market cover, and what was the market size in 2024?
In 2024, the Malaysia Insulin Infusion Pump Market size was estimated at USD 0.81 million. The report covers the Malaysia Insulin Infusion Pump Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Malaysia Insulin Infusion Pump Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
Malaysia Insulin Infusion Pump Market Report
Statistics for the 2025 Malaysia Insulin Infusion Pump market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Malaysia Insulin Infusion Pump analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
